Please provide your email address to receive an email when new articles are posted on . Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile ...
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) ...
PredictrPK ® ADA addresses the unmet need for individualized optimization of adalimumab (ADA) therapy in support of sustained clinical remission and drug persistence. SAN DIEGO, CA / ACCESSWIRE / July ...
HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...
SAN DIEGO, CA / ACCESS Newswire / June 17, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, announces the publication of a prospective, cross-sectional ...
HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results